These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24984921)

  • 1. MELD exceptions for portopulmonary hypertension: current policy and future implementation.
    Goldberg DS; Batra S; Sahay S; Kawut SM; Fallon MB
    Am J Transplant; 2014 Sep; 14(9):2081-7. PubMed ID: 24984921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Waitlist Mortality in Portopulmonary Hypertension.
    DuBrock HM; Goldberg DS; Sussman NL; Bartolome SD; Kadry Z; Salgia RJ; Mulligan DC; Kremers WK; Kawut SM; Krowka MJ; Channick RN
    Transplantation; 2017 Jul; 101(7):1609-1615. PubMed ID: 28207639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal Trends in Portopulmonary Hypertension Model for End-stage Liver Disease Exceptions and Outcomes.
    Del Valle KT; Krowka MJ; Heimbach JK; Taner T; DuBrock HM
    Transplant Direct; 2022 Dec; 8(12):e1410. PubMed ID: 36398194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mending the Model for End-Stage Liver Disease: An in-depth review of the past, present, and future portopulmonary hypertension Model for End-Stage Liver Disease exception.
    DuBrock HM; Del Valle KT; Krowka MJ
    Liver Transpl; 2022 Jul; 28(7):1224-1230. PubMed ID: 35106916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Waitlist Outcomes in Liver Transplant Candidates with High MELD and Severe Hepatic Encephalopathy.
    Gadiparthi C; Cholankeril G; Yoo ER; Hu M; Wong RJ; Ahmed A
    Dig Dis Sci; 2018 Jun; 63(6):1647-1653. PubMed ID: 29611079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
    Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
    J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OPTN policy regarding prioritization of patients with hepatopulmonary syndrome: does it provide equitable organ allocation?
    Sulieman BM; Hunsicker LG; Katz DA; Voigt MD
    Am J Transplant; 2008 May; 8(5):954-64. PubMed ID: 18416736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MELD Exceptions and Rates of Waiting List Outcomes.
    Massie AB; Caffo B; Gentry SE; Hall EC; Axelrod DA; Lentine KL; Schnitzler MA; Gheorghian A; Salvalaggio PR; Segev DL
    Am J Transplant; 2011 Nov; 11(11):2362-71. PubMed ID: 21920019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
    Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
    Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of liver transplantation for porto-pulmonary hypertension in model for end-stage liver disease era.
    Salgia RJ; Goodrich NP; Simpson H; Merion RM; Sharma P
    Dig Dis Sci; 2014 Aug; 59(8):1976-82. PubMed ID: 24557576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonstandard Exception Requests Impact Outcomes for Pediatric Liver Transplant Candidates.
    Braun HJ; Perito ER; Dodge JL; Rhee S; Roberts JP
    Am J Transplant; 2016 Nov; 16(11):3181-3191. PubMed ID: 27214757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the hepatopulmonary syndrome MELD exception policy on outcomes of patients after liver transplantation: an analysis of the UNOS database.
    Goldberg DS; Krok K; Batra S; Trotter JF; Kawut SM; Fallon MB
    Gastroenterology; 2014 May; 146(5):1256-65.e1. PubMed ID: 24412528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Center variation in the use of nonstandardized model for end-stage liver disease exception points.
    Goldberg DS; Makar G; Bittermann T; French B
    Liver Transpl; 2013 Dec; 19(12):1330-42. PubMed ID: 24039090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary contraindications, indications and MELD exceptions for liver transplantation: a contemporary view and look forward.
    Krowka MJ; Wiesner RH; Heimbach JK
    J Hepatol; 2013 Aug; 59(2):367-74. PubMed ID: 23557870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Share 21 model in liver transplantation: Impact on waitlist outcomes.
    Nagai S; Chau LC; Kitajima T; Yeddula S; Collins K; Rizzari M; Yoshida A; Abouljoud MS; Moonka D
    Am J Transplant; 2020 Aug; 20(8):2184-2197. PubMed ID: 32155314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
    Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
    Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Accuracy of Nonstandardized MELD/PELD Score Exceptions in the Pediatric Liver Allocation System.
    Ahn DJ; Zeng S; Pelzer KM; Barth RN; Gallo A; Parker WF
    Transplantation; 2023 Oct; 107(10):e247-e256. PubMed ID: 37408100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of rapid Model for End-Stage Liver Disease (MELD) increases for liver transplant registrant prioritization after MELD-Na and Share 35, an evaluation using data from the United Network for Organ Sharing.
    Brock GN; Washburn K; Marvin MR
    PLoS One; 2019; 14(10):e0223053. PubMed ID: 31581270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.
    Nobel YR; Goldberg DS
    Transplantation; 2015 Nov; 99(11):2341-6. PubMed ID: 25989503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes.
    Nagai S; Chau LC; Schilke RE; Safwan M; Rizzari M; Collins K; Yoshida A; Abouljoud MS; Moonka D
    Gastroenterology; 2018 Nov; 155(5):1451-1462.e3. PubMed ID: 30056096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.